Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
VTUS > SEC Filings for VTUS > Form 8-K on 5-Nov-2012All Recent SEC Filings

Show all filings for VENTRUS BIOSCIENCES INC



Other Events, Financial Statements and Exhibits

Item 8.01. Other Events.

On November 5, 2012, Ventrus Biosciences, Inc. issued a press release announcing that it had received written feedback from the U.S. Food and Drug Administration regarding its planned new drug application, or NDA, for diltiazem hydrochloride cream (VEN 307) in anal fissures and that, following completion of the recently begun Phase 3 clinical trial, it expects to file the NDA late in the fourth quarter of 2013. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Attached hereto as Exhibit 99.2, and incorporated herein by reference, is a PowerPoint presentation that Ventrus will present on its call scheduled for 10:00 a.m., Monday, November 5, to discuss VEN 307.

Item 9.01. Financial Statements and Exhibits.

  (d) Exhibits

      Exhibit No.   Description

      99.1          Press release dated November 5, 2012.

      99.2          PowerPoint presentation of November 5, 2012.

  Add VTUS to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for VTUS - All Recent SEC Filings
Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.